Publications by authors named "J-P Guillet"
Cancers (Basel)
July 2021
Article Synopsis
- Cemiplimab has shown promise in real-world use for locally advanced and metastatic cutaneous squamous-cell carcinomas (CSCCs), with a best overall response rate of 50.4% among treated patients.
- There was a median progression-free survival (PFS) of 7.9 months, and one-year overall survival (OS) was 73% for patients with better performance status (PS < 2).
- Although some patients experienced severe adverse events, the overall safety and efficacy indicate cemiplimab may be a beneficial treatment option, especially for immunocompromised individuals.
